Facts & Figures
India’s pharmaceutical industry is expected to expand at a compound annual growth rate (CAGR) of 22.4% in 2015–20 to reach $ 55 billion.
According to WHO, non-communicable diseases such as cancer, diabetes, and cardiovascular diseases have been collectively responsible for 70 per cent of all deaths worldwide.
Vildagliptin, a class of medication called dipeptidyl peptidase IV (DPP4) inhibitors, has about 25% share of the Indian gliptins market of Rs. 3,600 crore.
Over 68 per cent of cancer patients, over nearly two-thirds of cancer patients, are dying in India.
The market size for chronic Hepatitis B in India is estimated at Rs 140-crore.
According to USFDA’s definitions, OAI (official action indicated) means “objectionable conditions were found and regulatory administrative sanctions by FDA are indicated” during inspections.
According to Pharmexcil, India imported Rs. 17,400 crore worth of APIs from China in FY 2019.
Raw materials from China are used in making antibiotics, paracetamol, and diabetes and cardiovascular drugs, among others.
About 90% of the needs of antibiotic makers in India is fulfilled by China.
According to India’s drug regulatory body, the country has 1,500 plants that manufacture APIs.
The Ahmedabad-based company Torrent Pharmaceuticals is the only domestic pharma company that has invested nearly $1 billion in local acquisition over the last three years.
Wockhardt employs more than 7,000 people and has a presence in the US, Britain, Ireland, Switzerland, France, Mexico, Russia and other countries. It has manufacturing and research facilities in India, the US and Britain, and a plant in Ireland.
As per an August 2019 research report by ICICI Securities, Cipla currently has a 5% share of the domestic formulations business.
Spending on medicines in India is projected to grow 9-12% over the next five years, putting it in the top 10, according to the Indian Brand Equity Foundation’s October 2019 report on the country’s pharmaceutical sector.
Indian pharma companies total sales from the US market is estimated to be Rs 55 thousand crore.